Palvella Therapeutics, Inc. PVLA 深 沪
已收盘 05-15 16:00:00 美东时间
114.24
-4.730
-3.98%
华盛通- 最 高116.82
- 今 开116.82
- 成交量 25.84万股
- 最 低 111.56
- 昨 收 118.97
- 总市值 16.36亿
- 52周最高 151.18
- 市盈率 静 --
- 换手率 1.80%
- 52周最低 20.20
- 委 比 69.23%
- 总股本 1432.37万
- 历史最高 151.18
- 量 比 1.21
- 振 幅 4.42%
- 历史最低 11.17
- 每 手 1
- 风险率 36.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palvella Therapeutics Receives Approval To Uplist To Nasdaq Global Market
The transfer is effective at the opening of trading on Wednesday, May 13, 2026. The Company's common stock will continue to trade under its existing ticker symbol, "PVLA."The Nasdaq Global Market has higher initial and
05-13 19:33
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220
Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.
05-12 21:23
Palvella Announces First Patients Dosed In LOTU, Multicenter Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Clinically Significant Angiokeratomas
Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.Phase 2 single-arm,
05-04 19:36
Palvella Therapeutics To Highlight Results From Phase 3 SELVA And Phase 2 TOIVA Studies Of QTORIN Rapamycin At ISSVA World Congress 2026
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ETWAYNE, Pa., April 20, 2026 (GLOBE
04-20 19:32
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.
04-01 05:09
Palvella Therapeutics shares are trading higher. The company reported its Q4 financial results.
Palvella Therapeutics shares are trading higher. The company reported its Q4 fi...
04-01 00:35
Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate
Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.29 percent. This is a 79.89 percent increase over losses of $(5.37) per
03-31 19:31
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
